Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlycoFi Inc.

Division of Merck & Co. Inc.
www.glycofi.com

Latest From GlycoFi Inc.

Biologics Swing For The Fences: Payer Perspectives On Antibodies In Primary Care

Companies with large-molecule expertise increasingly are eyeing primary care markets, confident that improvements in safety and efficacy will make them competitive with oral standards of care.

BioPharmaceutical Business Strategies

Believing In Biosimilars: Industry Takes Long View on FDA Pathway

FDA is open for business on biosimilars as it works out the specifics of the new review pathway. But for companies considering an entry into the space, two big questions still remain: Does a profitable market exist, and how conservative will FDA be on those initial approvals? Executives from across the biopharmaceutical industry weigh in during The RPM Report’s FDA/CMS Summit.
BioPharmaceutical Platform Technologies

The Allure Of High-Hanging Fruit: Why VCs and Biotech Execs See Value In Difficult Drug Targets

An agile and energetic cohort of biotech platform companies plans to capture Big Pharma's imagination--and its pocketbook--by going after intractable drug targets that have long eluded the industry, and they're doing it on a shoestring budget.
BioPharmaceutical Business Strategies

In the Midst Of A Shakeout, Biotech VCs Must Embrace New Partners, New Math

With funds and firms closing, a new reality awaits those who survive until the next economic upswing. Some of the elements are already in place, such as VCs' willingness to take capped returns and exits via risk-sharing contingency-based acquisitions. The emphasis on capital efficiency may change the types of companies VCs can afford to back, and corporate funds are now a vital part of biotech venture, especially in the early stages.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Merck & Co. Inc.
  • Senior Management
  • Sylvie Gregoire, CEO
    Michael Horvath, CFO
    Charles Hutchinson, Pres.
  • Contact Info
  • GlycoFi Inc.
    Phone: (603) 643-8186
    21 Lafayette St.
    Ste. 200
    Lebanon, NH 03766
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register